Safety and efficacy of navitoclax, a BCL-2 and BCL-X_L inhibitor, in patients with relapsed or refractory lymphoid malignancies: results from a phase 2a study.

ABSTRACT: Navitoclax, a novel BCL-2 and BCL-X_L inhibitor, demonstrated promising antitumor activity in the dose-escalation part of a phase 1/2a study (NCT00406809) in lymphoid tumors. Herein, we report the continued safety and efficacy results of the phase 2a portion. Twenty-six adult patients with relapsed/refractory follicular lymphoma (n = 11, Arm A) and other relapsed/refractory lymphoid malignancies (n = 15, Arm B) were enrolled. Navitoclax administration schedule consisted of a 150-mg 7-day lead-in dose followed by 250-mg daily dosing with the option to further increase to 325 mg after 14 days if the 250-mg dose was tolerated. All patients experienced at least 1 treatment-related adverse event (TRAE). Seventeen (65.4%) patients reported grade 3/4 TRAEs; thrombocytopeni

SUBMITTER: de Vos S 

PROVIDER: S-EPMC9257998 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature